Table of Contents Table of Contents
Previous Page  520 / 812 Next Page
Information
Show Menu
Previous Page 520 / 812 Next Page
Page Background

S516

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

Aims

To analyze the occurrence and clinical particularities of dif-

ferent types of interictal depression in epilepsy patients.

Methods

One hundred and fourteen epilepsy patients with inter-

ictal depression were assessed with a clinical interview and

Hamilton depression and anxiety rating scales. Diagnostic criteria

of ICD-10 and of the International League Against Epilepsy (ILAE)

were used.

Results

A total of 45.6% of patients met ILAE criteria of iner-

ictal dysforic disorder (IDD) with predominance of depressive

mood, irritability, fear and atypical pain. All patients had chronic

epilepsy with specific epileptic personality changes. Comorbid

adjustment disorders (depressive and anxious-depressive reac-

tions) were diagnosed in 27.2% of patients. The most frequent

trigger situations were: family problems, serious illness, unem-

ployment, financial difficulties. In more than half of patients were

registered specific personality changes whose severity was in

inverse ratio with trauma severity. A total of 18.4% of patients

met criteria of comorbid affective disorder (depressive and bipo-

lar) with some specific clinical traits due to personality changes. In

8.8% of patients, anticonvulsant-induced depression was observed;

it was clinically simple, resolved after offending medication with-

drawal.

Conclusions

Observed depressive disorders were heteroge-

neous: comorbid or attributed to epilepsy or its treatment.

The most frequent condition was IDD. Specific personality

changes may contribute to higher susceptibility and develop-

ment of psychogenic depression. We emphasize the impor-

tance of treatment history (possibility of anticonvulsant-induced

depression).

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1506

EV522

Regulation of serum spadin

propeptide: An antidepressant

response probe

J. Mazella

, C. D

evader , M. Roulot , M. Borsotto , C. Heurteaux

Institut de pharmacologie moléculaire et cellulaire, CNRS–Life

science, Valbonne, France

Corresponding author.

Objectives

We previously discovered that spadin, a short ana-

logue of the propeptide (PE) released from the maturation of

sortilin, displays potent antidepressant properties. Since the PE

level can be measured in the blood, we aimed to investigate how

the PE serum concentration is regulated in mice. We wondered

whether the PE serum levels vary between healthy subjects and

patients with major depressive disorder (MDD).

Methods

We developped a dosing method based on the

AlphaScreen

TM

technology (Perkin) which allow to selectively

detect both PE, spadin and metabolic products from these peptides

with a detection range of 1 ng/mL.

Results

We found that insulin significantly up-regulated serum

PE concentration from 26.15

±

2.63 to 41.43

±

6.27 nM (

P

= 0.0318).

Analysis during circadian cycle in mice revealed that the amount

of PE and its derivatives significantly varied during the cycle being

higher during the period of maximal activity (dark period). We also

measured serum insulin concentration between 1 and 7 pm and

observed a significant rise confirming the relationships between

insulin and PE concentration. We showed that the serum level of

PE is lower in depressive patients than in healthy non-psychiatric.

We observed that the weaker level of PE in depressive patients can

recover the level of healthy subjects after a chronic antidepressant

treatment.

Conclusions

Dosing the serum level of PE could be a promising

approach for the diagnosis of depression and to determine the

remission of the disease.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1507

EV523

Treatment of mild to moderate major

depressive disorder with agomelatine

in patients with cardiovascular

disorders (national observational

multicenter study “pulse”)

V. Medvedev

Mosow, Russia

Introduction

The urgency of depression treatment in patients

with cardiovascular diseases (CVD) is determined by the increasing

prevalence of affective disorders. For these patients, tolerance and

safety of antidepressants are of great importance.

Objective

To obtain additional data on therapeutic efficacy and

tolerance of agomelatine in the treatment of mild to moderate

depressive disorders in cardiologic practice in Russia.

Methods

Eight hundred and ninety-six adult patients with CVD

(86.5% arterial hypertension, 29.5% stable angina, 16% myocardial

infarction, 23.6% conduction disturbances, 17.6% chronic heart-

failure) were treated with agomelatine 25-50mg for 12 weeks.

Depression and anxiety symptoms were evaluated via Hospital

Anxiety and Depression Scale (HADS), Clinical Global Impression

(CGI-S and CGI-I), Visual Analog Scale (VAS), Spielberger Anxiety

Scale (SAS), Whitely Hypochondria Index (WHI) and quality of life

questionnaire (SF-36). Safety and tolerance were also monitored

according to the summary of product characteristics recommen-

dations.

Results

HADS scores decreased throughout the study and severe

anxiety rate decreased from 95.9% to 15%. After 12 weeks of

treatment, remission (HADS < 7) rate was 84.6%. Subjective assess-

ment of patient health significantly improved (

P

< 0.00001). WHI

decreased significantly (

P

< 0.00001). Physical and mental health

significantly improved (

P

< 0.00001). Heart rate and blood pressure

decreased. Treatment acceptability was considered “excellent” by

82% of doctors and 75% of patients.

Conclusion

Agomelatine significantly improved depressive

symptoms, anxiety and hypochondria in depressed patients with

CVD and demonstrated good tolerance. This suggests the possibil-

ity of wide and safe use of agomelatine for treatment of depression

in patients with CVD.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1508

EV524

Premorbid temperament as a

predictor for remission in depression

J. Miettunen

1 ,

, R . M

arttila

2 , N.

Rautio

2 , E. R

oivainen

3 ,

S. Keinänen-Kiukaanniemi

2 , L. A

la-Mursula

2 , J. A

uvinen

2 ,

M. Timonen

2

1

Oulu, Finland

2

University of Oulu, Center for Life Course Epidemiology and Systems

Medicine, Oulu, Finland

3

Verve Rehabilitation, Oulu, Finland

Corresponding author.

Introduction

Personality traits have been associated with risk for

depressive disorders. Studies with premorbid measures on person-

ality are uncommon.

Objective

Estimate effect of premorbid personality as a predictor

for remission in depressive disorders.

Aim

To study premorbid personality as a predictor for remission

in depression in a population based sample.